# Acquired reactive perforating collagenosis treated with nemolizumab

**Authors:** Shehani T. Perera, Sofia Vescovacci, Sara Kaye Givens, Marc Inglese, András Schaffer, Austinn Miller

PMC · DOI: 10.1016/j.jdcr.2025.12.044 · 2026-01-05

## Full-text entities

- **Genes:** IL31 (interleukin 31) [NCBI Gene 386653] {aka IL-31}
- **Diseases:** diabetes mellitus (MESH:D003920), Hyperkeratosis (MESH:D017488), chronic kidney disease (MESH:D051436), inflammation (MESH:D007249), trauma (MESH:D014947), Perforating dermatoses (MESH:D012871), hyperpigmentation (MESH:D017495), metabolic dysregulation (MESH:D021081), itch (MESH:D011537), systemic disease (MESH:D034721), pruritic (MESH:C535817), ESRD (MESH:D007676), ARPC (MESH:C565687), necrotic (MESH:D009336), epidermal hyperplasia (MESH:D006965), PN (MESH:D011536), depression (MESH:D003866), perforating disorders (MESH:D057112)
- **Chemicals:** Hematoxylin (MESH:D006416), eosin (MESH:D004801), dupilumab (MESH:C582203), Nemolizumab (MESH:C000612881)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12962092/full.md

---
Source: https://tomesphere.com/paper/PMC12962092